Nonclinical Sciences & Technology

March 30 (Imaging)

Development of Radiopharmaceuticals: Fundamentals, Landscape, BD Deals, CMC Challenges, Theranostic Development, and IP strategies -

 Sponsored by PBSS 

  https://www.pbss.org/eventDetails/1042 

This workshop offers a comprehensive deep dive into the rapidly evolving field of radiopharmaceuticals. The agenda spans the full development lifecycle, beginning with a high-level view of the market landscape, deal-making trends, and future directions in oncology and beyond. Expert sessions will tackle critical technical hurdles, including CMC challenges, theranostic development, and manufacturing for first-in-human trials. Attendees will also gain insights into clinical strategies, such as dose selection and PET imaging agents, alongside essential legal considerations regarding IP strategy. 

March 31 (Nonclinical)

Drug Development and Delivery Day

https://pharmaforward.fiercelifesciences.com/pharmaforwardfierceli/drug-development-delivery-day?step=register

This program brings together leaders across biotech, pharma, and the broader development ecosystem to share practical, real-world strategies for keeping complex pipelines moving in today’s challenging funding and operating environment.

 

March 31 (Nonclinical/Tech)

Advance Your Translational Research with High-Plex Spatial Profiling

https://www.criver.com/education-training/webinar-pi-dsa-advance-your-translational-research-high-plex-spatial-profiling?utm_source=samktg&utm_medium=email&utm_campaign=sa-wbr-pathology-march26

• Decode the immune and tumor microenvironment to reveal meaningful spatial patterns and interactions
• Deepen your understanding of tissue organization and biological behavior through profiling of functional cell states
• Strengthen your biomarker strategies by integrating spatially resolved data that supports translational decision-making

 

April 8 (Nonclinical)

Advancing ADC Development: Leveraging AI and Translational Preclinical Models to Improve Clinical Predictability

https://insidescientific.com/webinar/advancing-adc-development-leveraging-ai-and-translational-preclinical-models-to-improve-clinical-predictability/?utm_bmcr_source=ISCmail

• Overcoming translational gaps in ADC development
• Leveraging AI for predictive modeling & biomarker strategy
• Using mouse clinical trials to enhance clinical relevance
• Understanding and modeling ADC resistance

 

April 9 (Nonclinical/ Tox)]

Multi-Stage AI Workflows for Regulatory Toxicology - From Chemical Structure to Complete Risk Assessment (Nura)

https://us06web.zoom.us/webinar/register/WN_lfknOzL7SHGg6jJVQRZsfw#/registration

Regulatory toxicology assessments require synthesizing evidence across dozens of data sources, computational tools, and regulatory frameworks. Traditional approaches require toxicologists to manually execute each step: query databases, run QSAR models, extract literature claims, format outputs, and compile sections into standardized templates. This manual orchestration is time-consuming, error-prone, and limits the number of chemicals that can be assessed.

 

Apri 9 (Nonclinical / Animal Models)

Exploring Biologics to Drive NK Cell Immunotherapy in Mouse Models of Human Cancer

Charles RiverLaboratories -  Sponsor

https://jackson.jax.org/jax-event-04092026.html?utm_source=marketo&utm_medium=email&utm_content=invite_1&utm_campaign=2026_04_09_webinar 

You’ll learn how mouse models, using different formats of human natural killer (NK) cells and human cancer cells, can be leveraged to evaluate the efficacy of biologics to amplify tumor control.

 

April 9 (Nonclinical / animal model)

Fulfilling the Gap: Innovative Critical Reagents for Non-Human Primate Preclinical Studies

https://insidescientific.com/webinar/fulfilling-the-gap-innovative-critical-reagents-for-non-human-primate-preclinical-studies/?utm_bmcr_source=ISCmail 

• Importance of NHP models in preclinical studies
• Current reagent gaps in preclinical studies of NHP
• Unique ABflo® rabbit mAbs developed for NHP flow cytometry
• High performance ABplex® Cytometric Bead Array (CBA) kits for accurate evaluation of NHP cytokines
• Precise assessment of Biomarkers in NHP biopsy using IHC and mIHC

 

April 22 (nonclinical)

Selecting disease-relevant models to derisk drug discovery

https://www.drugdiscoverynews.com/selecting-disease-relevant-models-to-derisk-drug-discovery-17055?utm_campaign=DDN%20Webinars&utm_medium=email&_hsenc=p2ANqtz--dycFwBCrIvzndRAInWHim70w0NBt5evvIf8abAE7YjvyPG-Ff3vbfAt-jo0r1H-bbhpcTIQeRdVZeXYNQaYlzeEm-jQ&_hsmi=408018813&utm_content=408018813&utm_source=hs_email 

Explore how advanced in vitro and in vivo model systems combined with high-throughput CRISPR screening improve translational confidence.

 

April  23 (Lab Animal)

Managing Aquatic Colonies: Navigating Different Waters

Charles River Labratories -Sponsor

https://www.criver.com/education-training/webinar-pi-rm-managing-aquatic-colonies-navigating-different-waters?utm_source=newsletter&utm_medium=email&utm_term=2026-03-25&utm_campaign=More%203Rs%20Webinars%20courses%20articles%20and%20more%20 

• Address challenges and establish best practices for setting up and maintaining aquatics programs
• Identify environmental factors and pathogens that could affect animal welfare
• Develop and implement an effective health monitoring program

 

April 28 (nonclinical)

Virtual Control Groups, Actually: What SEND Makes Possible (and What It Doesn’t)

https://www.certara.com/webinar/virtual-control-groups-actually-what-send-makes-possible-and-what-it-doesnt/?utm_source=linkedin.com&utm_medium=organic_social 

One emerging application is the use of virtual control groups (VCGs), which leverage historical control data to reduce or replace the use of concurrent control animals in toxicology studies.

 

May 19-20 (Nonclinical)

Pushing Boundaries in Emerging Infectious Disease Research

https://www.the-scientist.com/pushing-boundaries-in-emerging-infectious-disease-research-74026?utm_campaign=40167203-TS_Webinars_2026&utm_medium=email&_hsenc=p2ANqtz-8qSHmU5HEKF1UTpkNH8cdhwssg89viuxlH3sT-oiKI1Yd2gsYXCBxfPhz78UqGz9YZeabb8e_dsMD8bb7R53_-5ohKDw&_hsmi=408537955&utm_content=408537955&utm_source=hs_email

In this symposium, scientists will highlight innovative approaches for studying pathogens, monitoring infections, and mitigating infectious threats. 

------------------------------------------------------------

Novel Approach Methodologies / Microphysiological Systems

March 30 (MPS)

3RsC Heart MPS Webinar 

Day 1:  https://events.teams.microsoft.com/event/e0a0d451-3d28-44c9-a7ca-b9cdb3790adf@81a2e9ee-8eaf-4532-92a2-15eca7120774

Day 2:  https://events.teams.microsoft.com/event/75fa49d6-711f-4905-827f-3cfda6f50834@81a2e9ee-8eaf-4532-92a2-15eca7120774

This virtual symposium will consist of a series of short, 15-minute, data driven presentations overviewing each company's commercially available MPS platforms followed by a panel Q&A.   

Cardiotoxicity is a majory critical adverse event finding in pharmaceutical development.  MPS cardiac models offer great potential in de-risking cardiotoxicity.

 

Marh 31 (NAMs)

Modeling neurotropic viral infections using human cerebral organoids

https://www.drugdiscoverynews.com/modeling-neurotropic-viral-infections-using-human-cerebral-organoids-16988?utm_campaign=DDN%20Webinars&utm_medium=email&_hsenc=p2ANqtz-9_DJZzfu6sP2Tns25O6xeHO57dVp9kwDdyxOnsIypabb3p1Wd7BfvAjnlkxiqxP7R4WSCSf5ZPPyOKTY1ssRvuPreXSQ&_hsmi=405358649&utm_content=405358649&utm_source=hs_email 

• Modeling early human brain development with cerebral organoids
• Effects of Zika virus on organoid growth and tissue structure
• Large-area imaging and histological analysis of 3D brain models
• Scalable workflows for studying neurotropic viral infections 

 

April 7 (NAMs)

From Biopsy to Better Decisions: Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

https://insidescientific.com/webinar/from-biopsy-to-better-decisions-patient-derived-organoids-predict-treatment-response-in-metastatic-colorectal-cancer/?utm_bmcr_source=ISCmail    

• Explain why functional PDO testing is being pursued to improve response prediction in mCRC
• Identify patient- and process-related factors associated with successful PDO establishment from metastatic biopsies
• Describe the OPTIC study workflow and how PDO drug sensitivity was quantified (e.g., GRAUC/AUC, sensitivity cutoffs)
• Interpret the reported predictive performance for 5-FU/oxaliplatin (PPV/NPV, AUROC) and links to PFS/OS
• Discuss practical considerations and limitations for clinical implementation (timelines, standardization, next-trial needs)

 

April 7 (NAMs)

Predicting Chemotherapy Response with Patient-Derived Gastric Cancer Organoids

https://www.the-scientist.com/predicting-chemotherapy-response-with-patient-derived-gastric-cancer-organoids-74127?utm_campaign=38834271-TS_News%20Alerts_2026&utm_medium=email&_hsenc=p2ANqtz-_b6ix2UrKLyKU3g3IWSKyEVhhuXbrd7o7uaLVFlxuigZMJBIuaAqnRiEmYlgDD1E0vqaNgZadezFE1hnDI7AOfpn1YaQ&_hsmi=407354699&utm_content=407354699&utm_source=hs_email

• Understand how patient-derived gastric cancer organoids model tumor heterogeneity
• Learn how the Omni live-cell imaging platform generates quantitative and longitudinal readouts of organoid responses to FLOT chemotherapy in vitro
• Explore how functional drug profiling with organoid biobanks can support precision oncology approaches

 

April 8 (NAMs)

Advancing Drug Discovery with Complex Human In Vitro Models  

  https://www.the-scientist.com/advancing-drug-discovery-with-complex-human-in-vitro-models-73938?utm_campaign=TS%20Webinars&utm_medium=email&_hsenc=p2ANqtz-8LcVD6ek8QCpZ6CAuAw_I6hqEk2PXfuReLzG93n7LX3qeHLcHZTTDEpCChNYgH8C-6V-VaPtK3qdL5gdjtM7qwah0G3w&_hsmi=400847025&utm_content=400847025&utm_source=hs_email   

In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.

------------------------------------------------------------

Business Development

March 30

Top R&D trends in 2026: What’s in? What’s out? And what’s next?

https://events.endpoints.news/rnd15-2026/home?ref=eblast_0319&i=SlIBQLEKiRiTPLpSl3SCVtEGX511lgOT#registration 

We’ll be publishing John Carroll’s annual report on the R&D 15, offering an analysis of the top pipelines in the global industry. And accompanying that, Carroll will be moderating a one-hour conversation on top drug research trends, featuring several of the top R&D chiefs in the industry. What’s in? What’s out? And what’s next?

 

April 28-29 (BD)

From Bench to Start-up

https://www.the-scientist.com/from-bench-to-startup-74023?utm_campaign=TS%20Webinars&utm_medium=email&_hsenc=p2ANqtz--305KwtUXSQ-_lKK_c5_yCGsWeMyq9_SRo0-I7_mN4jFMl_gPkwrhl2ZImxyfLlka_EatYTVe0950FJSqbCf2NU5iiwA&_hsmi=404602446&utm_content=404602446&utm_source=hs_email 

Many academic researchers generate exciting discoveries in the laboratory, but translating those insights into real-world applications often requires taking a bold step into industry. To bring their vision to life, scientists establishing biotechnology startups must navigate a journey that blends rigorous research with strategic planning, team building, and funding. In this symposium, learn how scientists turned their discoveries into startup ventures.

April 23 (BD)

How to Lead a Biopharma Lab: Discovery to Delivery

https://www.labmanager.com/how-to-lead-a-biopharma-lab-discovery-to-delivery-35129?utm_medium=email&_hsenc=p2ANqtz-8jOQ7hi2Du7KCsF5_4MJfVObtSFNDN3wqEWwOLiHQLsFWF0jGOZ9KLDTDXL5up4-qy-EbMo8KQKOmJqdyrAszPFLA4Fg&_hsmi=410838864&utm_content=410839056&utm_source=hs_email 

• Leadership approaches that keep biopharma research aligned with clinical and business objectives
• Methods for managing cross-functional teams working on high-stakes projects
• Techniques to balance speed, compliance, and quality in drug development workflows
• Insights on fostering innovation while meeting tight timelines and regulatory expectations

 

 

---------------------------------------------------------------------------------------------------------------------------------------------------------------------